Skip to main content
Synbiotic SE logo

Synbiotic SE — Investor Relations & Filings

Ticker · SBX ISIN · DE000A3E5A59 LEI · 48510041U2G1IWA3R418 F Manufacturing
Open in API
Filings indexed 140 across all filing types
Latest filing 2025-04-17 Capital/Financing Update
Country DE Germany
Listing F SBX

About Synbiotic SE

https://www.synbiotic.com/

Synbiotic SE is a European corporate group focused on the medical cannabis and industrial hemp markets. The company operates a platform model, making strategic investments in ventures across these sectors to create synergies. Its business is vertically integrated, covering the entire value chain from cultivation, research, and development to the production, sales, and distribution of hemp- and cannabinoid-based products. The company's portfolio includes a wide range of high-quality hemp, CBD, and cannabis products, leveraging its expertise across the full supply chain from seed to shelf.

Recent filings

Filing Released Lang Actions
SYNBIOTIC SE: STRATEGISCHE PARTNERSCHAFT MIT IRIS CAPITAL INVESTMENT
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc Mitteilung' (Ad-hoc announcement) published on April 17, 2025, under Article 17 of EU Regulation No. 596/2014 (MAR). The content explicitly details a 'STRATEGISCHE PARTNERSCHAFT' involving the commitment by IRIS Capital Investment to subscribe to convertible bonds up to EUR 2.4 million. This action directly relates to fundraising, financing activities, and capital structure changes (issuance of convertible bonds). Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA), but a specific announcement about a financing event.
2025-04-17 German
SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time
Regulatory Filings Classification · 100% confidence The document is a short news release dated April 1, 2025, announcing a product launch: SYNBIOTIC presenting medical cannabis pastilles for the German market. It contains key highlights, quotes from management, and company boilerplate information. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing insider trades (DIRS) or voting results (DVA). Since it is an announcement of a significant corporate event (product launch) that doesn't fit the specific financial or governance categories, it is best classified as a general Regulatory Filing/News Announcement, which aligns with the RNS category, or potentially an Earnings Release (ER) if it were tied to financial results, but here it is purely operational/product news. Given the options, RNS (Regulatory Filings / General regulatory announcements) is the most appropriate fallback for a corporate news release that isn't explicitly an ER or RPA.
2025-04-01 English
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin
Regulatory Filings Classification · 100% confidence The document is a news release dated March 13, 2025, detailing SYNBIOTIC SE's participation in the International Cannabis Business Conference (ICBC) and discussing political and business aspects related to cannabis legalization and industrial hemp in Germany. It mentions upcoming product launches and solid sales figures, but it is primarily a corporate statement about industry engagement and outlook, not a formal financial filing like a 10-K, IR, or ER. The text ends with standard disclaimers typical of a press release distributed via EQS News. Since it is a general corporate announcement that doesn't fit the specific categories (like M&A, Dividend, or Director's Dealing), the most appropriate classification is the general regulatory announcement/press release fallback category, RNS (Regulatory Filings). The document length (8421 chars) is substantial enough that it is not just a brief announcement of a report (RPA).
2025-03-14 English
Quo vadis legalisation: SYNBIOTIC and GOC NEXUS at the International Cannabis Business Conference (ICBC) in Berlin
Regulatory Filings Classification · 100% confidence The document is a news release dated March 13, 2025, detailing SYNBIOTIC SE's participation in the International Cannabis Business Conference (ICBC) and discussing political and business aspects related to cannabis legalization and industrial hemp in Germany. It mentions upcoming product launches and solid sales figures, but it is primarily a corporate statement about industry engagement and outlook, not a formal financial filing like a 10-K, IR, or ER. The text ends with standard disclaimers typical of a press release distributed via EQS News. Since it is a general corporate announcement that doesn't fit the specific categories (like M&A, Dividend, or Director's Dealing), the most appropriate classification is the general regulatory announcement/press release fallback category, RNS (Regulatory Filings). The document length (8421 chars) is substantial enough that it is not just a brief announcement of a report (RPA).
2025-03-13 English
SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025
M&A Activity Classification · 99% confidence The document is a news release dated January 10, 2025, disseminated via EQS News. The content focuses on SYNBIOTIC SE's strategic activities, specifically announcing four new investments made in 2024 and outlining plans for further acquisitions in 2025. The key topic keywords are 'Mergers & Acquisitions' and 'Strategic Company Decision'. This type of announcement, detailing strategic corporate actions like acquisitions and future plans, fits best under the general category of corporate news that is not a formal financial report (like 10-K or IR) or a specific insider transaction (DIRS) or dividend notice (DIV). Since it is a strategic update about M&A activity and future direction, it aligns closely with the scope of 'M&A Activity' (TAR) or a general 'Regulatory Filing' (RNS). Given the explicit focus on 'acquisitions' and 'investments' as the core theme, 'TAR' (M&A Activity) is the most specific fit, although it is presented as a general news release. However, since the document is a comprehensive update on strategic M&A activity rather than just a brief announcement of a pending deal, and it is not a formal regulatory filing like a 10-K, it is best classified as a strategic update. If 'TAR' is strictly for takeover bids, then 'RNS' (Regulatory Filings/General Announcement) is the fallback. Given the strong emphasis on 'acquisitions' and 'investments', TAR is the most descriptive category for the content's substance, even if the format is a news release. I will select TAR as the primary classification based on content focus.
2025-01-11 English
SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025
M&A Activity Classification · 99% confidence The document is a news release dated January 10, 2025, disseminated via EQS News. The content focuses on SYNBIOTIC SE's strategic activities, specifically announcing four new investments made in 2024 and outlining plans for further acquisitions in 2025. The key topic keywords are 'Mergers & Acquisitions' and 'Strategic Company Decision'. This type of announcement, detailing strategic corporate actions like acquisitions and future plans, fits best under the general category of corporate news that is not a formal financial report (like 10-K or IR) or a specific insider transaction (DIRS) or dividend notice (DIV). Since it is a strategic update about M&A activity and future direction, it aligns closely with the scope of 'M&A Activity' (TAR) or a general 'Regulatory Filing' (RNS). Given the explicit focus on 'acquisitions' and 'investments' as the core theme, 'TAR' (M&A Activity) is the most specific fit, although it is presented as a general news release. However, since the document is a comprehensive update on strategic M&A activity rather than just a brief announcement of a pending deal, and it is not a formal regulatory filing like a 10-K, it is best classified as a strategic update. If 'TAR' is strictly for takeover bids, then 'RNS' (Regulatory Filings/General Announcement) is the fallback. Given the strong emphasis on 'acquisitions' and 'investments', TAR is the most descriptive category for the content's substance, even if the format is a news release. I will select TAR as the primary classification based on content focus.
2025-01-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.